Company: LBRX
Filing Date: 2025-08-22
Form Type: S-1
Source: 0001193125-25-186467
Chunk: 200

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-08-22
Form: S-1
Chunk 200
---
 Effect Size versus Placebo |      |
| 50 mg          |     |                            | 0.61 |
| 75 mg          |     |                            | 0.41 |
| 100 mg         |     |                            | 0.83 |

Effect Size versus Placebo in our Phase 2 trial. Secondary Endpoints Within this trial, responders were defined as those who had a 20% or greater reduction in PANSS score at Week 4 (floor-adjusted). The three dose cohorts achieved a responder rate of 31.9% (p=0.0587), 32.1% (p=0.0160), and 43.5% (p=0.0214) for the 50 mg, 75 mg, and 100 mg dose cohorts, respectively, compared to a responder rate of 18.3% for the placebo cohort. We also assessed response to treatment with LB-102using PANSS subscales for positive and negative symptoms, respectively. Looking specifically at positive symptom response, we observed a 4.8-pointdecrease (p=0.0051), 4.9-pointdecrease (p=0.0039), and 5.3-pointdecrease (p=0.0120) in the PANSS subscale for the 50 mg, 75 mg, and 100 mg dose cohorts, respectively, compared to a 3.1-pointdecrease in the placebo cohort. When looking at the negative symptom PANSS subscale, we observed a 2.2-pointdecrease (p=0.0116), 1.7-pointdecrease (p=0.1633), and 1.8-pointdecrease (p=0.2632) in the 50 mg, 75 mg, and 100 mg dose cohorts, respectively, compared to a 1.1-pointdecrease in the placebo cohort. LS Mean change in PANSS score from baseline to Week 4 in positive subscale. 140

LS Mean change in PANSS score from baseline to Week 4 in negative subscale.

We also conducted an exploratory post-hoc analysis of our Phase 2 data on the treatment effect in
patients with negative symptoms at baseline (i.e., those patients with a PANSS Negative Subscore greater than or equal to 24). In patients with negative symptoms at baseline, the LS Mean change in negative symptom scores at Week 4 was -1.6 (placebo